Q-omics provides the consensus-scored MIR924HG profile across patient tissues and cancer cell-line models. MIR924HG expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR924HG is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MIR924HG RNA expression shows 17,619 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KICH, KIRC, and LUAD as cancer lineages where MIR924HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR924HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR924HG survival associations across molecular data types. MIR924HG RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR924HG RNA expression–survival associations across cancer types. High MIR924HG expression shows unfavorable associations in KICH, MESO, CHOL, ACC, LGG and ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR924HG RNA expression.
This table summarizes MIR924HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR924HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR924HG shows higher tumor expression in KIRC, LUAD, THCA, LUSC, HNSC and KIRP. The KIRC box plot shows higher MIR924HG RNA expression in tumor versus normal tissue (log2 FC = +0.677, t-test p < 0.001).
This table shows molecular features associated with MIR924HG in patient tissues and cancer cell lines. In patient samples, MIR924HG shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
